Exelixis Inc (EXEL) reports robust financial results driven by the cabozantinib franchise, while navigating competitive and ...

By integrating EXL’s data and AI capabilities into the Genesys orchestration engine, enterprises gain the ability to transform customer interaction into a strategic lever for improving experience and ...

(Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and ...